Your browser doesn't support javascript.
loading
Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
Zhang, Wencheng; Yan, Cihui; Gao, Xuan; Li, Xiaoxia; Cao, Fuliang; Zhao, Gang; Zhao, Jingjing; Er, Puchun; Zhang, Tian; Chen, Xi; Wang, Yuwen; Jiang, Yao; Wang, Quanren; Zhang, Baozhong; Qian, Dong; Wang, Jun; Zhou, Dejun; Ren, Xiubao; Yu, Zhentao; Zhao, Lujun; Yuan, Zhiyong; Wang, Ping; Pang, Qingsong.
Afiliação
  • Zhang W; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Yan C; Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Gao X; Geneplus-Beijing Institute, Beijing, People's Republic of China.
  • Li X; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Cao F; Endoscopy Diagnosis and Therapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Zhao G; Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Zhao J; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Er P; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Zhang T; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Chen X; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Wang Y; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Jiang Y; Jiangsu Hengrui Medicine Co. Ltd., Lianyungang, People's Republic of China.
  • Wang Q; Jiangsu Hengrui Medicine Co. Ltd., Lianyungang, People's Republic of China.
  • Zhang B; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Qian D; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Wang J; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Zhou D; Endoscopy Diagnosis and Therapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Ren X; Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Yu Z; Esophageal Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Zhao L; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Yuan Z; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Wang P; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
  • Pang Q; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
Oncologist ; 26(7): e1110-e1124, 2021 07.
Article em En | MEDLINE | ID: mdl-33893689

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas do Esôfago / Neoplasias de Cabeça e Pescoço Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas do Esôfago / Neoplasias de Cabeça e Pescoço Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
...